A EUROPEAN Union-wide strategy to guarantee the production, supply and availability of medicines warding off the effects of a biological terrorist attack have been debated at a meeting between the European Commission and the EU pharmaceutical industry. They discussed possible threats, and how to ensure medicines are made available in emergencies. Options included the development of new treatments through market exclusivity incentives and fast-track authorisations. A policy paper on the subject is expected from the Commission this ...

Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.